Company / EPS (Diluted)
AVADEL PHARMACEUTICALS PLC EPS (Diluted) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.51
FY2024
5-year range
-$2.29 / $0.13
FY2020-FY2024
Trend
+74.5%
vs FY2023
Sector context
#73 of 204
Health Care
What the data says
At $-0.51, AVADEL PHARMACEUTICALS PLC's eps (diluted) ranks #73 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.55 in FY2018 to $1.63 in FY2017.
Based on SEC 10-K filings.
-0.51 in FY2024.
Improved from $-2.29 to $-0.51 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#73 of 204 in Health CareTop 36% of 204This company -$0.51 Sector average -$0.89
▼
+42.5% above sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 74.5% year-over-year.
- Ranks #73 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2017.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.51 | +74.5% |
| FY2023 | -$2.00 | +12.7% |
| FY2022 | -$2.29 | -73.5% |
| FY2021 | -$1.32 | -1115.4% |
| FY2020 | $0.13 | +114.6% |
| FY2019 | -$0.89 | +65.1% |
| FY2018 | -$2.55 | -256.4% |
| FY2017 | $1.63 | +263.0% |
| FY2016 | -$1.00 | -204.2% |
| FY2015 | $0.96 | +140.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026